Cancer is the second most common cause of death in the world and its incidence is increasing day by day. Doxorubicin (DOX) is an anthracycline group drug frequently used in many cancer treatments including breast cancer. However, free DOX has many harmful side effects and need to be encapsulated into nanocarrier such as liposomes. Although liposomal DOX has many advantages over its free form, liposomal DOX has undesirable side effects such as hand and foot syndrome. In this thesis, it was aimed to develop a more effective liposomal DOX delivery and release systems. Liposomes were prepared with alkaline solutions containing tris, sodium carbonate, ammonium chloride, and ammonium sulfate. DOX loading into liposomes and the percentage of release from liposomes were examined. A loading efficiency of about 80% was achieved, while the release was found to be below 13% at room temperature. The release of DOX was found to be enhanced from liposomes in the presence of ammonia (NH3), whose content was dependent on pH. Temperature was also found an important parameter and enhances DOX release at higher temperatures than the phase transition temperature of the lipid. A two-component liposomal system was proposed where ammonia (NH3) would be released from one liposome and enhance the DOX release from other liposomes. It was found that temperature, pH, and ammonia (NH3) concentration affected DOX release from liposomes. As a result, DOX was successfully loaded into liposomes and ready to study their effect on breast cancer cells.